Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.
Official title: A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
370
Start Date
2026-12
Completion Date
2032-03
Last Updated
2026-11-10
Healthy Volunteers
No
Conditions
Interventions
LY4336619
Administered IV
Sofetabart Mipitecan (Sofe-M)
Administered IV
Locations (23)
HonorHealth
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California, United States
The University of Chicago Medical Center (UCMC)
Chicago, Illinois, United States
Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center
Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics (START) - New York - Long Island
Lake Success, New York, United States
New York University (NYU) Clinical Cancer Center
New York, New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Rese -T
Columbus, Ohio, United States
MD Anderson Cancer Center
Houston, Texas, United States
START Mountain Region
West Valley City, Utah, United States
Centre Leon Berard
Lyon, France
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France
Oncopole Claudius Regaud
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Tokyo, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Marsden Hospital - Surrey
Sutton, United Kingdom